20,862 Gilead Sciences, Inc. $GILD Shares Sold by Vise Technologies Inc.

Vise Technologies Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 17.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 99,238 shares of the biopharmaceutical company’s stock after selling 20,862 shares during the period. Vise Technologies Inc.’s holdings in Gilead Sciences were worth $14,791,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of GILD. Bank of Nova Scotia acquired a new stake in shares of Gilead Sciences in the second quarter worth $100,056,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at $55,754,000. Groupe la Francaise lifted its holdings in shares of Gilead Sciences by 30.9% during the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock valued at $6,270,000 after acquiring an additional 11,712 shares in the last quarter. Baird Financial Group Inc. lifted its holdings in shares of Gilead Sciences by 3.6% during the 2nd quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock valued at $36,929,000 after acquiring an additional 10,206 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new position in shares of Gilead Sciences during the 2nd quarter valued at $6,251,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the sale, the director owned 10,066 shares of the company’s stock, valued at $1,459,771.32. This trade represents a 33.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the sale, the chief financial officer directly owned 161,096 shares in the company, valued at approximately $25,166,417.12. This trade represents a 1.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 96,000 shares of company stock valued at $13,923,210 in the last three months. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

GILD stock opened at $170.68 on Monday. The company has a current ratio of 1.32, a quick ratio of 0.95 and a debt-to-equity ratio of 2.03. The firm has a market cap of $211.63 billion, a P/E ratio of -54.01 and a beta of 0.35. Gilead Sciences, Inc. has a 12-month low of $114.02 and a 12-month high of $175.65. The stock’s 50 day simple moving average is $150.87 and its 200 day simple moving average is $139.79.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The company had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same period last year, the firm posted $2.47 EPS. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. As a group, equities research analysts predict that Gilead Sciences, Inc. will post -1.03 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -103.80%.

Wall Street Analyst Weigh In

GILD has been the subject of several recent research reports. Jefferies Financial Group reiterated a “buy” rating and issued a $185.00 price target on shares of Gilead Sciences in a report on Friday, October 23rd. Needham & Company LLC set a $175.00 price objective on Gilead Sciences in a research note on Friday. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. TD Cowen upped their target price on Gilead Sciences from $160.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday. Finally, HSBC increased their target price on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $169.19.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Several analysts raised their price targets for Gilead, setting targets of $175, $181, $183, $188, $190, and $200, while another raised its target to $131. The cluster of increases suggests improving confidence in Gilead’s earnings outlook and valuation. Gilead price target raised to $190 Gilead price target raised to $175 Gilead price target raised to $131 Gilead price target raised to $188 Gilead price target raised to $200 Gilead price target raised to $183 Gilead price target raised to $181
• Positive Sentiment: Morgan Stanley reiterated a Buy view on Gilead, adding to the positive analyst sentiment and supporting the case that the company’s HIV franchise and broader pipeline can sustain growth. Gilead receives a Buy from Morgan Stanley
• Positive Sentiment: Recent coverage points to strong HIV drug sales as a key reason GILD reached new highs. A separate investment article also highlighted Gilead as an attractive dividend-paying biotech, reinforcing its appeal to income-focused investors. Why GILD surged to 52-week highs Dividend-paying biotech stock article
• Neutral Sentiment: Gilead plans to present at upcoming fourth-quarter investor conferences, potentially giving management an opportunity to provide updates on its pipeline, commercial performance, and guidance. Gilead investor conference presentations
• Neutral Sentiment: A peer comparison and a separate analyst rating update provide additional valuation context, but the available headlines do not specify enough detail to determine a direct effect on GILD. Gilead and rivals comparison Gilead analyst rating update
• Negative Sentiment: Gilead’s third-quarter outlook contains a cautionary element: revenue guidance was raised, but the EPS outlook worsened. That contradiction may limit gains if investors focus on margins, expenses, or earnings quality despite the strength of the HIV business. Gilead third-quarter earnings analysis

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.